99% Purity Sofosbuvir Raw Material Sofosbuvir Powder Sofosbuvir

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: Dsung-Sofosbuvir
• Product Name: Sofosbuvir
• Other Name: Sovaldi
• Product Appearance: White Powder
• Application: Apis Raw Material
• CAS No: 1190307-88-0
• Mf: C22h29fn3o9p
• Grade Standard: Medicine Grade
• Shelf Life: 2 Years
• Storage: Cool Dry Place
• Packing: Bag,Drum
• MW: 529.45
• Test: HPLC,UV
• Melting Point: 120-125c
• Refractive Index: 1.573
• Density: 1.41
• Transport Package: Negotiable
• Specification: HPLC99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 3 Ton

Product Description

99% Purity Sofosbuvir Raw Material Sofosbuvir Powder Sofosbuvir

Product Description

 

 

Product Details

Product Nanme	Sofosbuvir
CAS NO.	1190307-88-0
Shelf Life	2Years
Storage	Cool Dry Place
Packing	Bag,Drum

Sofibuvir is a hepatitis C nucleoside analogue NS5B polymerase inhibitor, which can inhibit the NS5B gene on the hepatitis C RNA polymerase, so that the RNA strand of the hepatitis C virus cannot replicate, thus playing a role in killing the virus.
 

Application & Function

Sofibuvir inhibits HCV protein replication, thereby reducing or eliminating viral infection. Sofebuvir has the advantages of high safety, short treatment time and good tolerance. Not only can it replace traditional interferon therapy, but it can also be used in combination with other HCV drugs. With these advantages, sofibuvir has become the drug of choice for patients with chronic HCV infection. However, there are some side effects, such as nausea, fatigue, headache, itchy skin and insomnia. However, these side effects are uncommon and usually go away after treatment ends. Overall, sofabuvir is a very safe and effective drug that offers a relatively fast and no-significant side effect treatment regimen for HCV patients.
To sum up, sofabuvir is a very good drug, and its therapeutic effect has been well proven. As the technology continues to improve, we believe that in the future, sofibuvir and other novel drugs will be better able to help patients with chronic HCV infection recover.

Specification